Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Mary Mallaney"'
Autor:
M. Lia Palomba, Nilanjan Ghosh, Leo I. Gordon, Tanya Siddiqi, Mary Mallaney, David G. Maloney, Kathryn Newhall, Enkhtsetseg Purev, Matthew A. Lunning, Michael Wang, Jacob Garcia, Tina Albertson, Jon E. Arnason, Charalambos Andreadis, Scott R. Solomon, Daniel Li, Amitkumar Mehta, Jeremy S. Abramson, Alison R. Sehgal, Yeonhee Kim, Ken Ogasawara, Ana Kostic
Publikováno v:
Lancet (London, England). 396(10254)
Summary Background Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, chimeric antigen receptor (CAR) T-cell product. We aimed to assess the activity and safety of liso-cel in patients with relapsed or refractory large B-cell lympho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef8bd8826dbab2433f39fa131a55d53d
https://pubmed.ncbi.nlm.nih.gov/32958956
https://pubmed.ncbi.nlm.nih.gov/32958956
Publikováno v:
Biotechnology Progress. 30:562-570
During a small-scale cell culture process producing a monoclonal antibody, a larger than expected difference was observed in the charge variants profile of the harvested cell culture fluid (HCCF) between the 2 L and larger scales (e.g., 400 L and 12
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::765f7c88e7502aa2b3de777016d295c0
https://doi.org/10.1002/btpr.1920
https://doi.org/10.1002/btpr.1920
Autor:
Rachel K Yost, Brian Christin, Ronald J. Hause, Christopher Glen Ramsborg, Ryan P Larson, Heidi H. Gillenwater, Tina Albertson, Lauren F. Brown, Jeffrey Teoh, Paul Guptill, Timothy G. Johnstone, Mary Mallaney, Aditya Radhakrishnan, Neil A. Haig
Publikováno v:
Blood. 134:593-593
Background Lisocabtagene maraleucel (liso-cel) is an investigational, CD19-directed, genetically modified, autologous cellular immunotherapy administered as a defined composition of CD8+ and CD4+ components to deliver target doses of viable chimeric
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2983d65e91d98dbfef4beec5cea8cd03
https://doi.org/10.1182/blood-2019-127150
https://doi.org/10.1182/blood-2019-127150
Publikováno v:
Molecular pharmaceutics. 11(4)
Oxidative damage to proteins is one of the most prominent chemical degradation pathways that are of concern for drug product development in the biotechnology industry. Especially susceptible to oxidation are the Met and Trp residues in proteins. Whil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2896811672d6b5280b53b3e0ef0b44e8
https://pubmed.ncbi.nlm.nih.gov/24588659
https://pubmed.ncbi.nlm.nih.gov/24588659